Growth Opportunities in Onco-Immunotherapy, Genetic Therapy, Synthetic Biology, Microbiome Therapeutics: Featuring Bluebird Bio, Atara, Perseo Pharma & More – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Growth Opportunities in Onco-Immunotherapy, Genetic Therapy, Synthetic Biology, Microbiome Therapeutics” report has been added to ResearchAndMarkets.com’s offering.
This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) focuses on advanced autologous and allogeneic cell therapies for cancers. It also covers developments in ADCs and small molecules for multiple cancers. Few innovations for inflammatory diseases and infectious diseases have also been highlighted in this issue. Therapies which leverage nanotechnology and engineered nanoparticles for drug protection and drug design complement these innovations. Synthetic biology innovations around low cost gene synthesis and deployment of gene circuits have been featured as well.
The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Key Topics Covered:
Onco-Immunotherapy, Genetic Therapy, Synthetic Biology, Microbiome Therapeutics
- Tumor Microenvironment Targeted Therapies With An Improved Therapeutic Index
- Highly Selective Adc Platform
- Bioatla – Investor Dashboard
- Gene Therapies for Genetic Hematological Diseases
- One-Time Curative Gene Therapy for Scd
- Bluebird Bio – Investor Dashboard
- Autologus Cell Therapy for Advanced Melanoma
- Polyclonal Therapy Against Solid Tumors
- Instil Bio, Inc. – Investor Dashboard
- Immuno-Onco Therapies Against Solid Tumors
- Car-T Cell Therapy With Enhanced Cell Proliferation
- Bellicum Pharmaceuticals – Investor Dashboard
- Allogeneic Cell Therapy Against Solid Tumors and Hematological Cancers
- Off-The-Shelf Car T-Cell Therapy
- Allogene Therapeutics – Investor Dashboard
- Allogeneic T-Cell Therapy Without Gene Editing
- Off-The-Shelf Ebv-Targeting T-Cell Products
- Atara Bio – Investor Dashboard
- Tumor Prilferation Targeting Oral Kinase Inhibitor
- Small Molecule With Advanced Absorption, Distribution, Metabolism, and Excretion Properties
- Zentalis Pharmaceuticals – Investor Dashboard
- Macrophage Modifying Nanoparticle Platform With Anti Cancer Activity
- Technology Modulating Multiple Cell Types
- Nanotechnology-Protected Enzymes to Survive in the Gastrointestinal Environment
- Enhancing Enzyme Delivery Through Nanotechnology
- Perseo Pharma – Investor Dashboard
- Gene Therapy for Treating Life-Threatening Liver Disorders
- Single Administration Orphan Drug With Us Fast-Track Designation
- Vivet Therapeutics – Investor Dashboard
- Tailoring Cell Behavior With Precision
- Genetic Circuits That Provide Accurate Control Over Gene Programming
- Asimov – Investor Dashboard
- Understanding Gut Microbiomes and Their Interactions to Formulate Therapeutic Products
- Anti Inflammatory Live Biotherapeutics for Atopic Dermatitis
- Siolta Therapeutics – Investor Dashboard
- Gold Standard Customer Solution for Gene Synthesis
- Benefits of Quick Turnover and Error-Free Sequencing
- Eurofins Genomics Blue Heron – Investor Dashboard
- Metabolism Boosting Daily Wellness Supplements With Anti-Aging Benefits
- Nmn Causing Nad+ to Activate Sir2 Gene to Boost Metabolic Efficiency
- Eh – Investor Dashboard
- Point-Of-Care Device to Identify Bacteria in Urinary Tract Infections (Utis)
- Rapid Assay Delivering Accurate Results Comparable to Laboratory Tests
- Fq – Investor Dashboard
- Technology Regulating Immune Cells
- Immunotherapy Leading to Sustained Therapeutic Responses
- Bacteriophage-Based Treatment for Antibiotic-Resistant Bacterial Lung Infection
- National Jewish Health’s Technology Value Proposition
Key Contacts
- Legal Disclaimer
Companies Mentioned
- Bioatla
- Bluebird Bio
- Instil Bio, Inc.
- Bellicum Pharmaceuticals
- Atara Bio
- Zentalis Pharmaceuticals
- Perseo Pharma
- Vivet Therapeutics
- Asimov
- Siolta Therapeutics
- Eurofins Genomics Blue Heron
- EH
- FQ
For more information about this report visit https://www.researchandmarkets.com/r/k1ljkq
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
